Opiate and Opioid Use in Patients With Refractory Headache

Dk, Ziegler

doi:10.1046/j.1468-2982.1994.1401005.x

Cited by 39 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This emphasises the current opinion that caffeine-containing combinations should not be used, despite the enhancing analgesic effects of caffeine. True physical dependence has been reported in headache patients taking codeine and other opioids [49,50]. Even though some patients have been on codeine for > 10 years, no sufficient studies have investigated the possible effects of codeine intake over such a prolonged period of time.…”

Section: Pathophysiology and Pathogenesismentioning

confidence: 99%

Medication overuse headache

Obermann¹,

Bartsch

Katsarava³

2005

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Medication overuse headache (MOH) has developed into the third most common type of headache after tension-type headache and migraine. The prevalence of MOH is approximately 1% of the world's population and it shows an increasing trend as recent studies reveal a common involvement throughout the ages, even starting in childhood. All antiheadache drugs, such as triptans, analgesics, ergots and opioids, along with the common combination substances currently on the pharmacological market are capable of inducing MOH. New data on specific clinical features and mean critical monthly dosages and mean critical monthly intake frequencies are now available. The only effective treatment concept is consequent withdrawal therapy. Data of prospective studies on relapse rates and predictors of relapse after successful withdrawal therapy are presented.

show abstract

Section: Pathophysiology and Pathogenesismentioning

confidence: 99%

Medication overuse headache

Obermann¹,

Bartsch

Katsarava³

2005

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…Analgesics 46 (48) True physical dependence has been reported in headache patients taking codeine and other opioids [31,32]. Even though some patients have been taking codeine for over 10 years, no sufficient studies have investigated the possible effects of codeine intake over such a prolonged period of time.…”

Section: Critical Intake Dosage (Mg/mean Month [Sd])mentioning

confidence: 99%

Management of medication-overuse headache

Obermann

Katsarava

2007

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Medication-overuse headache (MOH) has developed into the third most common type of headache after tension-type headache and migraine. The prevalence reaches approximately 1% of the world's population and shows an increasing trend. Many important studies on MOH have been published in the last year, some of which investigated the pathophysiology of headache chronicity, with others focusing on the evaluation of risk factors. The International Headache Society revised its classification criteria on MOH. Several large population-based longitudinal studies clearly demonstrated that overuse of any kind of acute headache medication is the main risk factor leading to the development of chronic headache. Management of MOH remains difficult; the only effective treatment concept is consequent withdrawal therapy.

show abstract

“…Similarly, caffeine and meprobamat, the main metabolite of carisoprodol, should be removed from ergotamine-containing formulations. There are reports on physical dependence on codeine and other opioids in headache patients [18,19]. It should be remembered that up to 10% of codeine is metabolized to morphine.…”

Section: Pathophysiologymentioning

confidence: 99%

Analgesic/abortive overuse and misuse in chronic daily headache

Diener

Katasarva

2001

Current Science Inc

View full text Add to dashboard Cite

The frequent use (> 15 times/month) of medication for the treatment of acute migraine attacks may cause medication overuse headache. This kind of headache can be caused by the intake of combination analgesics, opioids, ergot alkaloids, and triptans. The delay between first intake and daily headache is shortest for triptans (1 to 2 years), longer for ergots (3 years), and longest for analgesics (5 years). Treatment includes drug withdrawal followed by structured acute therapy and initiation of migraine prophylactic treatment.

show abstract

Opiate and Opioid Use in Patients With Refractory Headache

Cited by 39 publications

References 26 publications

Medication overuse headache

Medication overuse headache

Management of medication-overuse headache

Analgesic/abortive overuse and misuse in chronic daily headache

Contact Info

Product

Resources

About